Physician profile
Eric J Carr
NPI 1093737447
$4,372.67
in general payments reported to CMS, 2019-2025
27 companies · $910 in 2025
The $910 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $458 · 2023: $1,649 · 2024: $1,355 · 2025: $910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.77 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $665.96 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $516.31 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $512.23 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $423.29 | 2022-2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $383.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $334.88 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $254.54 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $144.47 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.26 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $112.32 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $108.55 | 2023-2024 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $96.56 | 2022-2023 | Trintellix |
| Daiichi Sankyo INC. | $94.46 | 2024 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $92.55 | 2022 | |
| Merck Sharp & Dohme LLC | $77.50 | 2023-2025 | Capvaxive, Dificid, Gardasil 9 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $77.27 | 2023-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $63.79 | 2024-2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $63.42 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $60.15 | 2024-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $27.55 | 2023 | Eliquis |
| Neurelis, INC. | $25.59 | 2025 | Valtoco |
| Philips North America LLC | $20.98 | 2024 | (Ck6) Holter |
| Abbott Laboratories | $17.43 | 2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $17.18 | 2023 | Nuedexta |
| Genzyme Corporation | $16.78 | 2024 | |
| 3b Medical, INC. | $16.32 | 2025 | Luna |
| Boston Scientific Corporation | $15.56 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.